Arvinas to Present at the UBS Global Healthcare Virtual Conference
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, has announced that John Houston and Ian Taylor will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 10:00 a.m. ET. The event will be available via a live audio webcast and archived for 30 days on Arvinas' website. Arvinas aims to improve patient lives by developing therapies that degrade disease-causing proteins, with two clinical-stage programs: ARV-110 for prostate cancer and ARV-471 for breast cancer.
- None.
- None.
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.
A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com
Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com
FAQ
What is the date and time of the Arvinas fireside chat?
Where can I listen to the Arvinas presentation?
What are the clinical-stage programs of Arvinas?
What is the focus of Arvinas as a biotechnology company?
How long will the Arvinas webcast be available after the event?
